Merck has said its experimental cholesterol drug MK-859 raised levels of "good" HDL cholesterol by more than 50 percent in clinical trials, but without either raising blood pressure or causing serious cardiovascular side effects.
MK-859 is a member of the same class of medicines as torcetrapib, Pfizer's high-profile experimental medicine that was discontinued earlier this month after it was linked to elevated blood pressure and a worrisome number of deaths.
Great! Nothing to worry about there then.
Reuters
1 comment:
But, you forgot/left off the last sentence:
But Merck said its drug was associated with psychiatric side effects in clinical trials.
Maybe it causes people to kill so there will be deaths, just not for the patients (unless they live in a state with the death penalty)
Post a Comment